mac-1

Leukadherin-1 是 CD11b CD18 的变构激活剂，可增加 CD11b CD18 依赖性细胞对纤维蛋白原的粘附，减少白细胞运动和跨内皮迁移，具有抗炎作用。

MAC13243 HCl 是一种将脂蛋白从内膜运输到外膜的周质伴侣LolA的抑制剂，是一种具有特异性的抗菌剂，对革兰氏阴性菌抑制作用显著。

NMac1 (Nm23 activator 1) 是一种天然产物 cassumunene，从姜科植物 Zingiber cassumunar Roxb.中提取，在东亚传统上用作抗炎剂。NMac1 通过与 Nm23-H1 的 C 端直接相互作用，在体外激活其 NDP 激酶（NDPK）酶活性，具有抗转移潜力，并在体内实验中抑制乳腺癌转移。

(E)-NMac1 是一种可从爪哇姜中提取得到的化合物，可用于研究心血管疾病和神经系统疾病。

N-(3-Methoxybenzyl)Oleamide (MAC 18:1) 是一种从 Lepidium meyenii 中分离出来的玛瑙酰胺，对运动引起的疲劳具有药理作用，可能与调节能量代谢和改善抗氧化状态有关。

MAC13772 是一种 BioA 酶的有效抑制剂，IC50 为 250 nM，从而抑制生物素的生物合成。 MAC13772 具有抗菌活性。

MAC173979 inhibits E. coli de novo PABA biosynthesis and growth.

BpV(HOpic) (bpV (HOpic)) 是 PTEN 选择性抑制剂，IC50=14 nM。BpV(HOpic) 具有神经保护作用。

EMAC10101d 是 hCA II 选择性抑制剂(Ki:8.1 nM)。

Complement C5-IN-1 (Compound 7) 是补体成分蛋白5 (C5) 的小分子抑制剂。 Complement C5-IN-1 与 C5 相互作用以防止其被 C5 转化酶切割, 阻断酵母多糖诱导的 50％人全血 MAC 沉积的 IC50 值为 0.77 μM。

Complement factor D-IN-1 is an effective and selective small-molecule reversible factor d inhibitor (IC50s: 0.006 and 0.05 μM in FD Thioesterolytic Fluorescent Assay and a MAC Deposition Assay, respectively).

MAC glucuronide linker-1是一种ADC linker，可用于抗体偶联活性分子 (ADC)的构建，具有可降解的优点。

MAC glucuronide linker-2 is an ADC linker employed in the synthesis of ADCs, offering cleavability [1].

MAC glucuronide phenol-linked SN-38, a pH-sensitive lactone and DNA topoisomerase I inhibitor drug linker, exhibits cytotoxicity in L540cy and Ramos cells, with IC50 values of 113 ng mL and 67 ng mL, respectively[1].

MAC-VC-PABC-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity[1].

MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a stabilized lactone MAC glucuronide α-hydroxy lactone-linked SN-38 drug linker. MAC glucuronide α-hydroxy lactone-linked SN-38 is cytotoxic across L540cy cells and Ramos cells

iMAC2 是一种有效的MAC 抑制剂，IC50为 28 nM，LD50为15000 nM。iMAC2 显示出抗凋亡作用，并且iMAC2 阻断细胞色素 c 的释放。

JNJ-28610244 is a specific agonist of the H4 receptor. It acts by blocking Mac-1-dependent activation of p38 MAPK.

LL-37 is a cationic and α-helical antimicrobial peptide expressed in human bone marrow, testis, granulocytes, and gingival epithelium and is upregulated in psoriatic lesions. It inhibits growth of Gram-positive E. coli D21 and Gram-negative B. megatarium in a concentration-dependent manner and LL-37 expression is induced in A549 epithelial cells, alveolar macrophages, neutrophils, and monocyte-derived macrophages following M. tuberculosis infection. LL-37 binds sheep erythrocytes coated with S. minnesota Re-LPS and induces agglutination with a minimal agglutinating concentration (MAC) of 12.1 μg/ml. It is a chemoattractant for, and can induce calcium mobilization in, human monocytes, neutrophils, and T cells that naturally express formyl peptide receptor-like 1 (FPRL1) and FPRL1-transfected HEK293 cells. LL-37 (10-15 μM) pretreatment of dengue virus type 2 (DENV-2) reduces its infectivity as well as levels of viral genomic RNA and NS1 antigen. In vivo, LL-37 inhibits cecal ligation and puncture-induced caspase-1 activation and pyroptosis of peritoneal macrophages, reduces levels of the inflammatory cytokines IL-1β, IL-6, and TNF-α, and improves survival in polybacterial septic mice.

Fuzapladib (IS-741) (IS-741)是一种磷脂酶A2抑制剂，可以抑制细胞粘附分子Mac-1的表达。fuzpladib 阻断炎症细胞表面表达的粘附分子(integrin)的激活，阻止炎症细胞粘附血管内皮细胞和浸润组织，控制胰腺炎的恶化。

Lornoxicam-d4 is intended for use as an internal standard for the quantification of lornoxicam by GC- or LC-MS. Lornoxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties. It inhibits production of thromboxane B2 from arachidonic acid in HEL human erythroleukemic cells, which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F1α from arachidonic acid in Mono-Mac-6 cells, which endogenously express COX-2. Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC50 values of 65 and 54 µM, respectively. It reduces carrageenan-induced paw edema in rats when administered intravenously at doses ranging from 0.1 to 9 mg kg. Formulations containing lornoxicam have been used in the management of postoperative pain.

Abciximab (C7E3) 是一种小鼠 人嵌合单克隆抗体，是一种有效的糖蛋白 IIb IIIa (glycoprotein IIb IIIa) 抑制剂。 Abciximab 具有抗血小板聚集和白细胞粘附的作用，通过与糖蛋白 IIb IIIa、vitronectin 和 Mac-1 受体结合发挥作用。

γ-Fibrinogen377-395 TFA 是纤维蛋白原衍生抑制肽，具有纤维蛋白原表位特性。该化合物能在体外抑制小胶质细胞激活、阻断纤维蛋白与Mac-1相互作用，并在小鼠体内抑制实验性自身免疫性脑脊髓炎(EAE)。该肽适用于多发性硬化症(MS)及其他血脑屏障损伤和小胶质细胞激活相关的神经炎症疾病研究。

γ-Fibrinogen377-395是一种衍自纤维蛋白原的抑制性肽段，也被认为是纤维蛋白原的表位之一。它能在体外抑制小胶质细胞的激活并阻断纤维蛋白与Mac-1的交互作用；此外，在小鼠体内能够抑制实验性自身免疫性脑脊髓炎(EAE)的发展。因此，γ-Fibrinogen377-395对于多发性硬化症(MS)以及其他与血脑屏障损伤和小胶质细胞活化相关的神经炎症性疾病的研究具有潜在的应用价值。